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Publication of Secondary Analyses from Randomized Trials  
in Critical Care
To the Editor: The recent proposal by the Inter-
national Committee of Medical Journal Editors 
(ICMJE) requiring authors to make deidentified 
individual-patient data publicly available within 
months of publication of a clinical trial has gen-
erated much debate.1-3 The debate has focused on 
opportunity costs to the scientific community 
and the appropriate time frame for the primary 
investigators to conduct and report secondary 
analyses. There are scarce published data on the 
publication rates and factors influencing these 
rates and the time taken to publish secondary 
analyses from clinical trials.
We searched the New England Journal of Medi-
cine, JAMA, and The Lancet over an 11-year period 
from January 1, 2000, to December 31, 2010, for 
published randomized, controlled trials in crit-
ical care medicine. PubMed was searched for 
secondary publications up to April 2016 on the 
basis of the original publication. The effect of 
research trial-group status4 (established or inde-
pendent), study population, and funding source 
(industry or nonindustry) on publication of sec-
ondary analyses was examined (see the Supple-
mentary Appendix, available with the full text of 
this letter at NEJM.org).
We identified 81 randomized, controlled trials, 
with study population sizes ranging from 52 to 
125,132, from which 48 trials (59%) published 
152 substudies. Of these 47 trials, 20 (43%) had 
prespecified substudies (see the Supplementary 
Appendix). A higher percentage of trials con-
ducted by established research groups than by 
independent groups resulted in secondary publi-
cations (79% vs. 50%, P = 0.04), and trials con-
ducted by established groups were followed by 
more secondary publications than were trials 
conducted by independent groups (median of 
2 publications [interquartile range, 0 to 6] vs. 
0.5 publications [interquartile range, 0 to 2], 
P = 0.03) (Fig. 1). The median times from the 
publication of the first substudy and to the last 
substudy were 2 years (interquartile range, 0 to 8) 
and 5 years (interquartile range, 1 to 10), respec-
Figure 1. A Box-Plot Comparison of Substudy Publications 
between Independent and Established Trial Groups.
The horizontal bar inside each box is the median, the 
top and bottom of the box indicate the interquartile 
range, the T bars indicate the 95th percentiles, and  
the circles indicate outliers. RCT denotes randomized, 
controlled trial.
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tively. The rate of secondary publications did not 
differ significantly between industry-funded and 
nonindustry-funded studies (45% and 41%, re-
spectively; P = 0.88 by chi-square test).
In randomized, controlled trials in critical 
care medicine that were published in the ICMJE 
journals with the highest impact factor, a sub-
stantial proportion of trials do not produce sec-
ondary publications. Because established trial 
groups are more likely to publish secondary 
analyses than independent groups, this difference 
may represent a missed opportunity in advanc-
ing scientific discovery and hypothesis genera-
tion that could be addressed through responsible 
data sharing. There appears to be a considerable 
delay between the publication of original and 
secondary analyses. We submit that these ob-
servations be taken into consideration in devel-
oping guidelines for data sharing to maximize 
opportunities and benefits for primary and sec-
ondary investigators. (Our database will be made 
available 6 months after the publication of this 
letter.)
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Perioperative Ledipasvir–Sofosbuvir for HCV in Liver-Transplant 
Recipients
To the Editor: Hepatitis C virus (HCV) infec-
tion continues to be the most frequent indication 
for liver transplantation, but recurrence of infec-
tion is nearly universal in patients who are vire-
mic at the time of transplantation.1 Direct-acting 
antiviral agents (DAAs) have been shown to be 
effective in treating recurrent HCV infection2,3 
but have not been tested in preventing reinfec-
tion at the time of liver transplantation. Be-
cause HCV RNA levels fall precipitously after 
liver transplantation owing to removal of the 
liver, the immediate perioperative period before 
rebound of viremia represents a unique oppor-
tunity to cure HCV infection.4 We hypothesized 
that a DAA regimen shorter than the standard 
12 to 24 weeks starting immediately before the 
transplantation might prevent reinfection of the 
new graft.
We conducted an open-label, multicenter, phase 
2 study (ClinicalTrials.gov number, NCT02350569) 
involving wait-listed patients with chronic HCV 
genotype 1 infection who were undergoing a first 
liver transplantation from an HCV-negative donor. 
Patients who had received previous DAA treat-
ment or who had a creatinine clearance of less 
than 40 ml per minute at the time of transplan-
tation were excluded. A total of 37 patients were 
screened, and 16 with a median unadjusted 
Model for End-Stage Liver Disease score of 13 
(on a scale from 6 to 40, with higher scores in-
dicating more advanced liver disease) were en-
rolled (Fig. S1 and Table S1 in the Supplemen-
tary Appendix, available with the full text of this 
letter at NEJM.org). Patients received a single dose 
of ledipasvir (90 mg)–sofosbuvir (400 mg) the 
day they arrived at the hospital for transplanta-
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